

METABOLISM

Estrogen receptor α controls metabolism in white and brown adipocytes by regulating *Polg1* and mitochondrial remodeling

Zhenqi Zhou¹, Timothy M. Moore¹, Brian G. Drew¹, Vicent Ribas¹, Jonathan Wanagat², Mete Civelek³, Mayuko Segawa¹, Dane M. Wolf¹, Frode Norheim³, Marcus M. Seldin³, Alexander R. Strumwasser¹, Kate A. Whitney¹, Ellen Lester¹, Britany R. Reddish¹, Laurent Vergnes³, Karen Reue³, Prashant Rajbhandari⁴, Peter Tontonoz⁴, Jason Lee⁵, Sushil K. Mahata^{6,7}, Sylvia C. Hewitt⁸, Orian Shirihai¹, Craig Gastonbury⁹, Kerrin S. Small⁹, Markku Laakso¹⁰, Jorgen Jensen¹¹, Sindre Lee¹², Christian A. Drevon¹², Kenneth S. Korach⁸, Aldons J. Lusis³, Andrea L. Hevener^{1,13*}

Obesity is heightened during aging, and although the estrogen receptor α (ER α) has been implicated in the prevention of obesity, its molecular actions in adipocytes remain inadequately understood. Here, we show that adipose tissue *Esr1/Esr1* expression inversely associated with adiposity and positively associated with genes involved in mitochondrial metabolism and markers of metabolic health in 700 Finnish men and 100 strains of inbred mice from the UCLA Hybrid Mouse Diversity Panel. To determine the anti-obesity actions of ER α in fat, we selectively deleted *Esr1* from white and brown adipocytes in mice. In white adipose tissue, *Esr1* controlled oxidative metabolism by restraining the targeted elimination of mitochondria via the E3 ubiquitin ligase parkin. mtDNA content was elevated, and adipose tissue mass was reduced in adipose-selective parkin knockout mice. In brown fat centrally involved in body temperature maintenance, *Esr1* was requisite for both mitochondrial remodeling by dynamin-related protein 1 (Drp1) and uncoupled respiration thermogenesis by uncoupled protein 1 (Ucp1). In both white and brown fat of female mice and adipocytes in culture, mitochondrial dysfunction in the context of *Esr1* deletion was paralleled by a reduction in the expression of the mtDNA polymerase γ subunit *Polg1*. We identified *Polg1* as an ER α target gene by showing that ER α binds the *Polg1* promoter to control its expression in 3T3L1 adipocytes. These findings support strategies leveraging ER α action on mitochondrial function in adipocytes to combat obesity and metabolic dysfunction.

INTRODUCTION

Accumulation of excess fat underlies the development of obesity and metabolic dysfunction, and the clustering of metabolic abnormalities contributes to the development of chronic diseases, including type 2 diabetes, cardiovascular disease, and certain types of cancer (1). Although premenopausal women are less prone to metabolic-related diseases than men (1), this protection is lost during menopause, associating with a rapid increase in central adiposity (1). New findings from the Study of Women's Health Across the Nation show that

during the menopausal transition, beginning several years before the final menstrual period, the mean rate of increase in fat mass nearly doubles in the average woman (2). The aging-associated rise in adiposity observed in both women and men is an important clinical outcome that requires greater mechanistic insight and improved therapeutic targeting. A link between mitochondrial dysfunction and adiposity has been postulated (3–6), as mitochondria-related transcriptional signatures are differentially expressed in adipocytes of healthy monozygotic twins discordant for obesity (3). Similar to genes associated with mitochondrial biogenesis, *ESR1*, the gene encoding the estrogen receptor α (ER α), is also reduced in adipose tissue from obese women (7). Although we have previously shown that selective deletion of ER α from adipocytes promotes increased adipocyte size and total adiposity as well as disruption of metabolic homeostasis in both male and female rodents (8), the molecular mechanisms underlying these phenotypes remain inadequately understood.

Distinct from white adipose tissue (WAT), the major fat storage depot of the body, brown adipocytes are characterized by the uncoupling of mitochondrial respiration from adenosine triphosphate (ATP) synthesis for the production of heat in thermoregulation (9). During cold exposure, mitochondrial remodeling shifts substrate metabolism to fatty acid mobilization linked with the induction of uncoupling protein [uncoupled protein 1 (UCP1)] to produce heat (10–16). Activation of brown adipose tissue (BAT) and WAT browning are thought to contribute to improvements in metabolic homeostasis and insulin action (17–22). Females have an increased abundance

¹Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, CA 90095, USA. ²Division of Geriatrics, Department of Medicine, University of California, Los Angeles, CA 90095, USA. ³Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. ⁴Department of Pathology and Laboratory Medicine and the Howard Hughes Research Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. ⁵Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. ⁶VA San Diego Healthcare System, San Diego, CA 92161, USA. ⁷Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. ⁸Receptor Biology Section, NIEHS, NIH, Research Triangle Park, NC 27709, USA. ⁹Department of Twin Research and Genetic Epidemiology, King's College London, London SE17EH, UK. ¹⁰Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio 70210, Finland. ¹¹Department of Physical Performance, Norwegian School of Sport Science, Oslo 0806, Norway. ¹²University Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo 0316, Norway. ¹³Iris Cantor-UCLA Women's Health Research Center, Los Angeles, CA 90095, USA.

*Corresponding author. Email: ahevener@mednet.ucla.edu

of BAT that is more highly responsive to activation and more highly enriched in mitochondria compared with males (23, 24). Moreover, recent reports show that BAT metabolism and WAT beiging are induced by estradiol (25, 26). Considering these observations, we set out to determine the relationship between adipose tissue *Esr1* expression and adipocyte metabolism. We used Cre-Lox to generate mouse models in which *Esr1* was selectively deleted in WAT or BAT. Because we have shown in other metabolic cell types that ER α directly controls mitochondrial DNA (mtDNA) replication as well as fission–fusion–mediated mitochondrial remodeling and turnover (27, 28), we interrogated the impact of ER α on mitochondrial function in white and brown adipocytes and determined whether the molecular links we established in rodents are relevant in humans.

RESULTS

Adipose tissue *ESR1* expression is inversely associated with adiposity and positively associated with insulin sensitivity

An overview of our human and mouse studies is displayed in fig S1. To provide a clinical rationale for studies in genetically engineered rodents, we first examined clinical relationships between *ESR1* and surrogate markers of metabolic health. We found that expression of *ESR1* in adipose tissue was highly heritable as the narrow sense heritability (the fraction of the variance of a trait that is explained by additive genetic factors) determined for *ESR1* expression in adipose tissue biopsies from female monozygotic and dizygotic twin pairs was 29% ($n = 766$, aged 38 to 85 years) (29). In this cohort of women, adipose tissue *ESR1* expression inversely correlated with percent fat mass (Bicor -0.308 , $P = 2.29 \times 10^{-9}$) and plasma insulin (Bicor -0.025 , $P = 1.69 \times 10^{-5}$). Similarly, *ESR1* expression in adipose tissue of male participants enrolled in the Skeletal Muscles, Myokines, and Glucose Metabolism (MyoGlu) study inversely associated with visceral adipose tissue mass (Fig. 1A) and positively correlated with whole-body insulin sensitivity [glucose infusion rate (GIR) as determined by glucose clamps] (Fig. 1B). In addition, we observed a reduction in *ESR1* expression in adipose tissue from dysglycemic men compared to normoglycemic controls (Fig. 1C). Because exercise is known to induce *ESR1* and mitochondrial biogenesis in muscle, we studied these endpoints in subcutaneous adipose tissue from men after 90 days of exercise training. *ESR1* expression was increased in adipose tissue of normoglycemic men but remained unchanged from sedentary baseline in adipose tissue of prediabetic dysglycemic men (Fig. 1D). Similar to our observations from the MyoGlu studies, we observed inverse relationships between adipose tissue *ESR1* and fat mass as well as the insulin resistance index Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants participating in the much larger Metabolic Syndrome in Men (METSIM) study (Fig. 1, E and F). Moreover, in this same population of men, we detected a strong inverse correlation between adipose expression of *ESR1* and oral glucose tolerance (Bicor -0.36 , $P = 1.91 \times 10^{-25}$; 120 min plasma glucose) and insulin area under the curve (Bicor -0.409 , $P = 3.54 \times 10^{-32}$).

Similar to human participants, adipose tissue *Esr1* expression inversely correlated with fat mass (Fig. 1, G and H) and the insulin resistance index HOMA-IR (Fig. 1, I and J) in a collection of 100 strains of male and female inbred mice known as the University of California, Los Angeles (UCLA) Hybrid Mouse Diversity Panel (HMDDP). Expression analyses revealed a substantial overlap between *ESR1/ESR1*-correlated genes in adipose tissue from METSIM, MyoGlu,


and the HMDDP, signifying the reproducibility of findings between mouse and human (Fig. 1K and table S1). These data obtained from human participants suggest that *ESR1* expression in adipose tissue is a strong surrogate marker of metabolic health.

Esr1 regulates the expression of the mtDNA polymerase *Polg1* and associates with markers of mitochondrial function in adipose tissue

Because male and female mice from the UCLA HMDDP showed an inverse relationship between *Esr1* and adiposity, we performed RNA sequencing (RNA-seq) analyses on fat from this mouse panel to determine the highly correlated *Esr1* genes overlapping between the sexes. Of the 685 genes that highly correlated with *Esr1* ($P < 0.0001$) in both sexes of the standard experimental mouse strain C57BL/6J, none were discordant in the direction of correlation (Fig. 2A and table S2). The biological process gene ontology (GO) terms associated with the gene overlap included metabolic processes (Fig. 2B). To refine our understanding of the ER α -regulated pathways in adipocytes and determine the molecular underpinnings contributing to the *Esr1*-adiposity relationship, we generated mice with *Esr1* selectively knocked out in either WAT [adiponectin Cre; fat specific ER α KO (FERKO)] or BAT (UCP1 Cre; ER α KO^{BAT}). As previously shown by our group (8), we confirmed *Esr1* deletion in gonadal (gWAT) and inguinal (iWAT) fat depots in both male and female mice as well as increased adipose tissue mass in both fat pads of FERKO mice (Fig. 2C and fig. S2, A to D). In addition, FERKO mice were hyperinsulinemic, hyperleptinemic, and glucose intolerant when fed a high-fat diet (HFD) compared to Control^{fl/fl}, as previously described (8). To determine the pathways disrupted by *Esr1* deletion and contributing to the increase in adiposity, we performed gene arrays on gWAT from FERKO and Control^{fl/fl} mice. Functional annotation classification revealed significant enrichment scores ($P < 0.01$) for mitochondria (table S3), nucleotide binding, transcription, DNA repair, helicase, and protein transport (Fig. 2D).

Because we have previously shown that ER α regulates mitochondrial function, dynamics, and turnover in a variety of cell types (27, 28), we next assessed the impact of ER α on mitochondrial biology specifically in fat. Although white adipocytes contain far less mitochondria than brown adipocytes, we observed a 70 to 80% reduction in mtDNA copy number in gWAT from both female and male FERKO mice compared with control ER α -replete mice (Fig. 2, E and F). This observation is consistent with reduced mtDNA copy number in fat from obese and type 2 diabetic subjects (30). Similarly, we also observed reduced mtDNA copy number in subcutaneous fat from dysglycemic compared to normoglycemic men (Fig. 2G). Moreover, we observed a strong positive correlation between *ESR1* expression and mtDNA copy number in subcutaneous fat from middle-aged men (Fig. 2H). These data were supported by the observation that *Ppargc1a* and genes encoding proteins of the tricarboxylic acid cycle and electron transport chain were reduced in adipose tissue of dysglycemic compared to normoglycemic men (fig. S3, A to C). Next, we assessed the expression of standard markers of mitochondrial biogenesis in mouse gWAT and found that although there was no difference between the genotypes for *Pgc1a*, *Tfam1*, or *Polg2* (which encodes the accessory subunit of polymerase γ), there was a marked reduction in *Pgc1b*, *Nrf1*, *Polg1* (which encodes the catalytic subunit of polymerase γ), and *Polrmt* (which encodes the primary mitochondrial RNA polymerase) in FERKO compared to Control^{fl/fl} (Fig. 2, I and J). These findings suggest that mtDNA replication and

Fig. 1. Adipose tissue *ESR1*/*Esr1* expression is strongly associated with adiposity and insulin sensitivity. (A and B) Subcutaneous white adipose tissue *ESR1* expression in relation to visceral adipose tissue volume as determined by MRI and insulin sensitivity as assessed by the glucose clamp technique (GIR, glucose infusion rate). **(C)** *ESR1* expression in adipose tissue of dysglycemic men (DG) compared with normoglycemic (NG) men of the MyoGlu study ($n = 13$ NG controls and $n = 11$ DG; age 40 to 65 years). **(D)** Adipose tissue *ESR1* expression in normoglycemic and dysglycemic men after exercise. **(E and F)** Correlations of adipose tissue *ESR1* expression with fat mass (percentage) and the insulin resistance index HOMA-IR from the METSIM study ($n = 770$ men, age of 45 to 70 years). **(G to J)** *Esr1* expression in gonadal adipose tissue from male and female HMDP mice (4 mice per strain, ~100 strains per sex) versus adipose tissue mass (%) and HOMA-IR. **(K)** Venn diagram depicting overlap in *ESR1*/*Esr1* by gene correlations (midweight bicorrelation) in adipose tissue from METSIM, MyoGlu, and HMDP studies. Statistical analysis between each pairwise group indicates the overlaps in gene expression to be significantly more probable than predicted (RF, representation factor; $**P < 0.001$; $***P < 0.0001$). Data are means \pm SEM. Mean differences were detected using Student's *t* test or one-way ANOVA, and correlations were determined by Pearson's *r*. $*P < 0.05$ between groups NG versus DG. # $P < 0.05$ within group pre-exercise versus postexercise difference. NS, not significant; RPKM, reads per kilobase million; AU, arbitrary units.




transcription may be under the control of ER α in adipocytes. In FERKO gonadal fat, we confirmed a reduction in the total protein of polymerase γ , POLG, the only known mammalian mtDNA polymerase involved in the replication of the mitochondrial genome (Fig. 2, J to L). Despite a marked reduction in mtDNA copy number, we did not detect a difference in protein abundance of representative subunits of the electron transport chain in fat between mice of different genotypes (Fig. 2M); these findings are similar to the observations made for ER α -deficient versus ER α -replete skeletal muscle

(27) and suggest that the kinetics of protein turnover may be altered by the absence of ER α .

To confirm a direct effect of ER α on expression of mitochondrial-related genes, we knocked down ER α on expression of mitochondrial-related genes, we knocked down ER α on 3T3L1 adipocytes using lentiviral particles containing short hairpin RNA (shRNA) against *Esr1* (Fig. 2N). Similar to FERKO fat, we observed a reduction in mtDNA copy number, representative subunits of the electron transport chain complexes, and markers of mitochondrial biogenesis (Pgc1a, Nrf1, and Tfam) in *Esr1*-knockdown (KD) 3T3L1 adipocytes

Fig. 2. ER α deficiency reduces *Polg1* and mtDNA copy number in white adipose tissue.

(A) *Esr1*-correlated genes ($P < 0.0001$) in WAT of the male and female C57BL/6J mice and **(B)** the overlapping *Esr1* genes represent metabolic processes. **(C)** Gonadal adipose tissue weight in male and female mice lacking ER α in fat. **(D)** Functional annotation analysis of the processes disrupted by adipose tissue ER α deletion in female FERKO mice. **(E and F)** mtDNA copy number in adipose tissue from male and female FERKO mice ($n = 6$ to 8 mice per genotype), as well as **(G)** adipose tissue from dysglycemic versus normoglycemic men ($n = 11$ to 13 per group). **(H)** Correlation of *ESR1* with mtDNA abundance in human subcutaneous fat ($n = 24$ men). **(I)** *Pgc1b*, *Nrf1*, *Pgc1a*, and *Tfam1* expression in gonadal fat from female FERKO mice ($n = 5$ to 6 mice per genotype). **(J to L)** *Polg1*, *Polg2*, and *Polrmt* mRNA and POLG1, TFAM, and Pgc1 α protein in gonadal fat from female Control^{fl/fl} and FERKO mice ($n = 5$ to 6 mice per genotype). **(M)** Abundance of specific subunits of the electron transport chain between the mouse genotypes. **(N)** *Esr1* deletion in 3T3L1 adipocytes and its impact on **(O)** mtDNA copy number, **(P to R)** markers of mitochondrial biogenesis (*Pgc1a*, *Nrf1*, *Tfam*, *Polg1* and *Polg2*), and representative subunits of the electron transport chain ($n = 3$ in triplicate per condition). **(S and T)** Maximal respiration and respiratory reserve capacity (RCR), assessed by real-time respirometry in 3T3L1 adipocytes lacking ER α ($n = 5$ per condition). **(U)** Fatty acid esterification rates using ¹⁴C palmitate in *Esr1*-KD 3T3L1 adipocytes compared to scrambled control (Scr). Data are means \pm SEM. Student's *t* test or one-way ANOVA, * $P < 0.05$ between groups. GAPDH, glyceraldehyde phosphate dehydrogenase; FPKM, fragments per kilobase million; TFAM, mitochondrial transcription factor A; CN, copy number; nuDNA, nuclear DNA.



in culture (Fig. 2, O to Q). This was paralleled by a reduction in *Polg1* expression in *Esr1*-KD versus scrambled control 3T3L1 adipocytes, similar to FERKO versus Control^{fl/fl} WAT (Fig. 2R). These alterations in gene expression in adipocytes lacking ER α likely contributed to the reduction in maximal cellular respiration and mito-

chondrial respiratory reserve capacity (Fig. 2, S and T) as well as the increased rate of lipid esterification (Fig. 2U). In aggregate, these findings show that ER α controls mtDNA copy number and the expression of *Polg1*, a primary regulator of mtDNA replication and function.

ER α regulates *Polg1* expression and mtDNA copy number by direct binding to the *Polg1* promoter

Because mtDNA copy number was reduced in the context of ER α deletion, we next treated wild-type (WT) 3T3L1 adipocytes with 17 β -estradiol (E₂; 10 nM) to determine whether ER activation could induce *Polg1* expression (Fig. 3A). *Polg1* was induced as early as 1 hour after E₂ treatment and was sustained for up to 16 hours before returning to baseline by 24 hours of E₂ stimulation (Fig. 3A). Next, we determined the mechanism of ER α -induced expression of *Polg1*. We performed chromatin immunoprecipitation (ChIP) studies in 3T3L1 adipocytes and showed that E₂ promoted ER α binding to several sites in the *Polg1* promoter (Fig. 3B). To ascertain whether the reduction in *Polg1*/POLG expression in the context of ER α deficiency drove the reduction of mtDNA copy number in adipocytes, we performed transient *Polg1* KD studies in primary adipocytes and in 3T3L1 cells using Cre-Lox and lentiviral-mediated approaches, respectively. *Polg1* expression and POLG protein abundance were reduced in both models of *Polg1* gene deletion (Fig. 3, C to E), paralleled by a significant reduction in mtDNA copy number ($P = 0.04$ and $P = 0.0003$, respectively; Fig. 3, F and G).

ER α controls parkin protein abundance and its cellular localization

Because mtDNA replication is intimately linked with mitochondrial division (31) and feedback control of mitochondrial turnover (31), we next interrogated fission and mitophagic signaling. Internally consistent with a reduction in both *Polg1* expression and mtDNA replication, the outer mitochondrial membrane docking protein mitochondrial fission 1 protein (FIS1) and phosphorylation of the mitochondrial fission regulator Drp1 (dynamin-related protein 1) at its activation site Ser⁶¹⁶ were reduced in *Esr1*-KD compared with ER α -replete adipocytes (Fig. 4, A to C). To understand the mechanisms contributing to the reduction in mtDNA copy number, we assessed mitophagic signaling. Although expression of *Park6* [gene that encodes PTEN-induced kinase 1 (PINK1)] and *Park2* (gene that encodes parkin) was identical between genotypes (fig. S4, A and B), PINK1 and parkin protein from whole-cell lysates were elevated in FERKO fat (both gWAT and iWAT) and *Esr1*-KD adipocytes versus respective controls (Fig. 4, D to H). The increase in parkin protein was paralleled by a marked reduction in its putative outer mitochondrial membrane target, the fusion protein Mfn2 (Fig. 4, I and J). This observation is congruent with parkin action to promote mitochondrial separation from the network and organelle elimination by lysosomal degradation. Next, we performed fractionation studies to determine parkin localization. Although total protein was elevated in the lysates of *Esr1*-KD versus control adipocytes (Fig. 4, F and H), parkin protein was reduced by 85% ($P = 0.009$) in the cytosol of *Esr1*-KD compared to control but significantly elevated (32%; $P = 0.005$) in the mitochondrial fraction of *Esr1*-KD versus control adipocytes (Fig. 4, K and L).

Because the stress protein p53 is an ER α target and binds parkin to regulate mitophagy (32) and because p53 is induced with HFD feeding and prevents being of WAT (33, 34), we interrogated the role of p53 in controlling parkin localization in the context of ER α overexpression (fig. S4, C to E) and deficiency (fig. S4, F and G). The mitochondrial:cytosolic distribution of parkin mirrored that of p53 in 3T3L1 adipocytes (fig. S4, D to G). We determined that mitochondrial distribution of p53 was reduced in the context of ER α overexpression and increased as a consequence of ER α deletion. To




Fig. 3. ER α controls *Polg1* expression and mtDNA copy number by direct binding to the *Polg1* promoter. (A) The impact of estradiol (E₂ 10 nM over time; closed bars) on *Polg1* expression in 3T3L1 adipocytes ($n = 3$ per time point). (B) ChIP studies of ER α and the *Polg1* promoter in 3T3L1 adipocytes ($n = 3$ experiments in duplicate). (C and D) Transient deletion of *Polg1* in primary adipocytes from *Polg1*-floxed mice using AAV-Cre or in 3T3L1 adipocytes using lentivirus, (E) POLG protein, and (F and G) mtDNA copy number [$n = 3$ experiments in duplicate, AAV-Cre versus AAV-GFP control and scrambled control (Scr) versus *Polg1*-KD]. Data are means \pm SEM. Student's t test or one-way ANOVA, * $P < 0.05$ between groups or treatment conditions.

test this relationship further, we chemically disrupted the binding of p53 to parkin by incubating cells with Pifithrin- α (PFT; 10 to 50 μ M for 5 hours). Inhibition of p53 led to nearly undetectable amounts of parkin in the mitochondrial fraction of adipocytes (fig. S4, H to J). These findings are consistent with observations of increased mtDNA copy number and reduced adiposity in p53^{-/-} mice (34–36).

To determine the role of parkin in the regulation of adiposity, we studied gonadal fat from Parkin^{KO} mice and observed that mtDNA copy number was elevated 1.8-fold ($P = 0.04$) compared to WT animals (Fig. 4M). Increased mtDNA copy number was paralleled by reduced fat weight (relative to total body weight; Fig. 4N) (37). We next confirmed the reduction in fat pad size in adipose-selective parkin




Fig. 4. ER α controls mitochondrial fission-fusion-mitophagy signaling. (A to C) FIS1 protein and p-Drp1^{Ser616} compared with scrambled control (Scr) in *Esr1*-KD 3T3L1 adipocytes ($n = 3$ biological replicates per group in duplicate). (D and E) Parkin protein in gWAT and iWAT of FERKO mice versus Control^{f/f} ($n = 4$ to 6 per genotype). (F to H) PINK1 and parkin protein expression and (I and J) Mfn1 and Mfn2 protein in 3T3L1 adipocytes with *Esr1*-KD versus scrambled control ($n = 3$ biological replicates per group in duplicate). (K) Parkin protein blots and (L) densitometric analysis of cytosolic and mitochondrial fractions in *Esr1*-KD and scrambled control (Scr) 3T3L1 adipocytes. (M) Adipose tissue mtDNA copy number and (N) fat mass in whole-body parkin null mice ($n = 5$ to 8 per genotype). (O) Images

of gWAT, iWAT, and BAT from adipose-selective parkin knockout (*Parkin*^{AdiKO}) mice compared with Control^{f/f}. (P) Parkin protein immunoblots and (Q) densitometric analysis in lysates from 3T3L1 adipocytes with *Polg1* KD ($n = 3$ biological replicates per group in duplicate). Data are means \pm SEM. Student's *t* test or ANOVA, * $P < 0.05$ between the genotypes or groups.

knockout mice (*Parkin*^{AdiKO}) and observed that the fat pads harvested from the two parkin deletion models were darker in color compared with respective controls (Fig. 4O) (40). Last, we investigated the relationship between *Polg1* expression and parkin protein abundance, finding that parkin protein was induced 2.5-fold ($P = 0.01$) in adipocytes with *Polg1* KD (Fig. 4, P and Q). Together, these data show enhanced parkin redistribution to the mitochondria by a p53-regulated mechanism (33, 34) in ER α -deficient adipocytes and

suggest a link between mtDNA replication and mitophagic signaling in white adipocytes.

ER α deletion drives autophagic turnover of mitochondria in WAT

Consistent with the notion of reduced mitochondrial content in ER α -deficient adipocytes, we observed that markers of macroautophagy required for mitochondrial turnover by the lysosome, including




Fig. 5. ER α controls macroautophagy signaling and mitophagic flux in white adipocytes. (A to D) Beclin1 and Atg7 protein and LC3B processing (I and II) in gonadal fat from FERKO versus Control^{fl/fl} mice ($n = 5$ to 6 mice per genotype). (E) Autophagy signaling in *Esr1*-KD 3T3L1 adipocytes ($n = 3$ in triplicate) and in (F) *Polg1*-KD adipocytes. (G) Mtpagy Dye, LysoTracker Green, and merged images and quantification of (H) the number of lysosomes per cell, (I) total lysosome area per cell, (J) total mitolysosomes per cell, and (K) total mitolysosome area per cell in *Esr1*-KD adipocytes versus scrambled control (Scr) cells ($n = 3$ independent experiments). (L) Mitochondrial membrane potential ($\Delta\Psi_m$) determined by TMRE staining [50 nM; relative to MitoTracker Green (MTG) for quantification of mitochondrial size (M)] and assessed by confocal microscopy (images in fig. S4). (N) Mitochondrial membrane potential ($\Delta\Psi_m$) variability (SD) on a per-cell basis in *Esr1*-KD adipocytes versus scrambled control (Scr). (O) mtDNA copy number in gonadal fat of FERKO mice treated with leupeptin, an inhibitor of lysosomal-mediated autophagy ($n = 4$ mice per treatment group). Data are means \pm SEM. Student's *t* test or one-way ANOVA, * $P < 0.05$ between genotypes.

Beclin, Atg5, Atg7, and Atg12, and LC3B processing, were elevated in FERKO mouse fat and *Esr1*-KD 3T3L1 adipocytes compared to respective controls (Fig. 5, A to E). KD of *Polg1* reproduced a similar increase in upstream and downstream autophagic markers Beclin1 and LC3BII, respectively (Fig. 5F). To show that ER α controls mitophagic flux in white adipocytes, we used a dual-label fluorescence tag and performed confocal microscopy to visualize the colocalization of mitochondria with lysosomes (Fig. 5, G to K). MtpHagy Dye and LysoTracker Green quantification showed a marked increase in colocalization of mitochondria with lysosomes in *Esr1*-KD adipocytes (Fig. 5, J and K). We assessed mitochondrial membrane potential, critical for generating ATP by oxidative phosphorylation by tetramethylrhodamine ethyl ester perchlorate (TMRE) as previously described (Fig. 5L) (38).

Mitochondrial membrane potential is a key indicator of cellular health, and a reduction in membrane potential initiates the accumulation of PINK1 to promote mitochondrial turnover (39, 40). Although recent evidence shows that reduction in *Polg1* expression, similar to that observed in *Esr1*-KD cells, diminishes overall cellular membrane potential in human embryonic kidney 293 cells (41), we detected no difference in overall mitochondrial membrane potential between the two genotypes of cells [Fig. 5L, TMRE relative to MitoTracker Green (MTG) fluorescence; fig. S5]. However, mitochondrial size was reduced in *Esr1*-KD cells (Fig. 5M). Because recent work showed that different cristae within an individual mitochondrion can have disparate membrane potentials, we assessed the variability of membrane potential per cell (38). This comparison revealed that mitochondrial membrane potential variability was increased in cells lacking ER α (Fig. 5N). These data are consistent with the observation that interventions aimed at promoting mitochondrial depolarization may affect some cristae while sparing others and that polarized cristae maintain a higher potential than neighboring depolarized cristae. Therefore, a mitochondrial hetero-potential arising from the compartmentalization of the mitochondrial membrane potential along the inner mitochondrial membrane may render the cell more vulnerable to metabolic stress. Our findings support the notion that increased mitophagy underlies the reduction in mtDNA copy number and impairment of oxidative metabolism in *Esr1*-deficient fat, which we confirmed, in part, by restoring mtDNA copy number in FERKO fat via leupeptin (LPT)-induced inhibition of autophagic proteases within the lysosome (Fig. 5O). Although more work is required to understand the mechanisms linking mtDNA replication and turnover via mitophagy, the findings related to the role of ER α in the control of adipocyte metabolism provide insight into the fat accumulation observed during conditions of reduced estrogen action such as the menopausal transition.

ER α regulates UCP1 induction and substrate metabolism in brown adipocytes

Considering that females have increased BAT and enhanced thermogenic capacity (23, 24), we confirmed that *Esr1* and *Ucp1* expression and mitochondrial content were higher in BAT from WT female versus male mice (Fig. 6, A and B). Moreover, during cold exposure, *Esr1* expression was induced fourfold in BAT of female mice (Fig. 6C), suggesting that ER α may play an important role in BAT metabolism and thermoregulation. HFD and genetic obesity reduced expression of *Esr1*, as well as *Polg1* and *Polg2*, genes that respectively encode the catalytic and accessory subunits of POLG (Fig. 6D); thus, environmental perturbations appear to disrupt estrogen action, and these

signaling defects may underpin the well-known diet-induced alterations in energy homeostasis. To understand the actions of ER α in brown adipocytes, we used the UCP1 Cre recombinase mouse (42) to generate animals with a BAT-specific *Esr1* knockout (ER α KO^{BAT}) (Fig. 6E and fig. S6, A to D). Consistent with our hypothesis, we observed a 42% reduction ($P = 0.002$) in *Ucp1* expression in the basal state and a markedly blunted response ($P = 0.006$) of *Ucp1* to cold challenge in ER α KO^{BAT} versus Control^{fl/fl} animals (6 hours at 4°C; Fig. 6F).

Reduced ER α expression by experimental *Esr1* deletion in BAT increased body weight gain and WAT accumulation during HFD feeding of female ER α KO^{BAT} versus Control^{fl/fl} (Fig. 6, G and H). During extended duration cold tolerance testing, body temperature was reduced for ER α KO^{BAT} at later time points during the test compared with Control^{fl/fl} mice (Fig. 6I). Histological analyses revealed that BAT lacking ER α accumulated a greater number of large lipid droplets (Fig. 6J), so although ample substrate was available to fuel thermogenesis, lipid droplet utilization may have been impaired in ER α KO^{BAT} mice. We performed transmission electron microscopy and found that mitochondria in BAT of ER α KO^{BAT} mice had thinner cristae and an increased perimeter and area (Fig. 6, K to M). In contrast to FERKO WAT, we observed no difference in BAT mtDNA copy number between ER α KO^{BAT} and Control^{fl/fl} mice (Fig. 6N). Although mtDNA copy number was identical between the groups, we observed a marked reduction in *Polg1* expression in BAT from ER α KO^{BAT} compared with floxed controls (Fig. 6O). The reduction in *Polg1* expression in BAT of ER α KO^{BAT} was similar to our observation in WAT of FERKO mice. The reduction in *Polg1* was paralleled by a reduction in total protein and activation signaling of the mitochondrial fission protein DRP1 (Fig. 6, P to R). In contrast to WAT, however, parkin protein expression in BAT was identical between ER α KO^{BAT} and Control^{fl/fl} (Fig. 6, P and S) and was not elevated over control as seen in ER α -deficient WAT from FERKO mice. Moreover, mRNA and protein of the macroautophagy marker LC3B was reduced in BAT of ER α KO^{BAT} compared to control (LC3BI and LC3BII; fig. S7, A to C). These findings for parkin and macroautophagy likely underpin the differential observation of mtDNA copy number between BAT versus WAT in the context of ER α deficiency. Our findings confirm a differential regulation of mitophagy in WAT versus BAT that is mediated by divergent downstream responses to the reduction in *Polg1* expression in the context of ER α deletion (43).

Esr1 deletion drives a greater reliance on glucose metabolism for thermoregulation

Because we observed a blunted induction of *Ucp1* and reduced mitochondrial fission signaling in BAT of ER α KO^{BAT} mice, we hypothesized that the increased lipid storage phenotype was a consequence of impaired lipid mobilization and reduced fatty acid oxidation (44). To test a shift in substrate reliance between the genotypes during cold stress, we performed fluorodeoxyglucose F18 (¹⁸FDG) MicroCT-PET (positron emission tomography) imaging after a 6-hour cold challenge. Even at room temperature, glucose uptake into BAT was increased in ER α KO^{BAT} compared to Control^{fl/fl} mice, and this elevated glucose reliance in BAT of ER α KO^{BAT} was heightened during cold stress (Fig. 7, A and B) when fatty acid oxidation is typically maximized. The increased reliance on glucose as fuel to maintain body temperature caused a marked reduction (49%; $P = 0.002$) in circulating blood glucose in ER α KO^{BAT} mice during cold challenge, whereas Control^{fl/fl} mice maintained euglycemia for the duration of cold exposure




Fig. 6. ERα controls Ucp1 induction, mitochondrial morphology, and thermogenic capacity of BAT. (A) Sex difference in *Esr1* and *Ucp1* expression and (B) mtDNA copy number in BAT of male and female WT mice ($n = 5$ to 6 mice per sex). (C) *Esr1* expression is induced in BAT of WT female mice during cold challenge (5 hours, 4°C) versus room temperature (RT). (D) Expression of *Esr1*, *Polg1*, and *Polg2* in HFD-fed or with genetic obesity (*Lep^{Ob/+}*) with NC-fed WT mice ($n = 5$ to 6 mice per group). (E) Confirmation of ERα deletion in BAT from female ERαKO^{BAT} mice ($n = 6$ per genotype). (F) *Ucp1* expression in BAT at room temperature and impaired

Ucp1 induction during cold challenge (5 hours, 4°C) in female ERαKO^{BAT} mice versus Control^{f/f}. (G) Body weight during early HFD feeding of female ERαKO^{BAT} versus Control^{f/f} ($n = 5$ to 6 per genotype). (H) WAT, inguinal (iWAT) and gonadal (gWAT), in female ERαKO^{BAT} versus Control^{f/f} under normal chow (NC) and high-fat diet (HFD) feeding ($n = 5$ to 6 mice per genotype). (I) Body temperature in ERαKO^{BAT} versus Control^{f/f} over time during cold challenge (5 hours, 4°C). (J) Increased lipid droplets in BAT from ERαKO^{BAT} versus Control^{f/f} detected by histochemistry ($n = 3$ per genotype). (K) Transmission electron microscopy showing mitochondrial architecture in ERαKO^{BAT} versus Control^{f/f}, with mitochondrial images quantified for (L) perimeter and (M) area. (N) mtDNA copy number determined by quantitative PCR (qPCR) in BAT from male and female ERαKO^{BAT} versus Control^{f/f} ($n = 5$ to 6 mice per genotype; normalized to 1.0). (O) *Polg1* expression in BAT of female ERαKO^{BAT} versus Control^{f/f}. (P to S) Immunoblots and corresponding densitometry showing (Q) parkin protein expression, (R) Drp1 total protein, and (S) Drp1^{Ser600} phosphorylation in ERαKO^{BAT} versus Control^{f/f} ($n = 5$ to 6 mice per genotype). Data are means ± SEM. Student's *t* test or one-way ANOVA, * $P < 0.05$ between the genotypes or sexes. # $P < 0.05$ within group and between conditions.

(Fig. 7C). These findings in BAT suggest that in the absence of ERα, *Polg1* (a direct ERα target) is markedly reduced, and mitochondria become metabolically dysfunctional because of a feedback im-

pairment of mitochondrial fission remodeling. Our findings suggest that ERα controls a mtDNA replication architecture remodeling nexus to dictate metabolism and cellular health of adipose tissue (fig. S8).




Fig. 7. ER α deletion alters substrate metabolism in BAT during cold stress. (A and B) ^{18}F FDG MicroCT-PET imaging of glucose utilization in BAT of ER $\alpha\text{KO}^{\text{BAT}}$ mice and Control^{fl/fl} at room temperature (22°C) as well as after a 6-hour cold challenge at 4°C. (C) Blood glucose in ER $\alpha\text{KO}^{\text{BAT}}$ during cold stress compared with Control^{fl/fl}. Data are means \pm SEM. Student's *t* test or one-way ANOVA, **P* < 0.05 between genotypes. #*P* < 0.05 within genotype and between conditions.

DISCUSSION

Accumulation of excess fat underlies the development of obesity and metabolic dysfunction, and these contribute to the progression of chronic diseases that challenge Western society, including type 2 diabetes, cardiovascular disease, and certain types of cancer (1). Although premenopausal women are less prone to metabolic disease compared with men (1), menopause reverses this metabolic protection, equalizing disease risk between the sexes (1, 2). The aging-associated rise in fat accumulation in both women and men is an important clinical outcome that requires improved mechanistic insight. Although mitochondrial dysfunction is commonly linked with adiposity (3–6), and *ESR1*, a gene linked with mitochondrial function (27, 45), was shown to be reduced in adipose tissue from obese women (7), the mechanistic links between these relationships remain unresolved. Because females have higher expression of *ESR1/Esr1* and higher mtDNA copy numbers in WAT and BAT compared to males (23), we studied the relationships between *ESR1/Esr1* expression, mitochondrial function, and adiposity in humans and mice.

Our findings in fat biopsies from monozygotic and dizygotic twins show strong heritability of *ESR1* expression in adipose tissue. We provide evidence in humans and rodents, confirming that natural expression of *ESR1/Esr1* in fat is inversely correlated with adiposity independent of sex. Because mitochondrial content in fat is reduced in obese and diabetic subjects (3, 5, 46) and gene expression analyses identified mitochondrial genes as most highly associated with *ESR1* in fat from humans and rodents (27, 28), we focused our efforts in

this area. Our findings are consistent with a role for ER α in regulating adiposity by controlling mitochondrial function in WAT and BAT. We observed a marked difference in mtDNA copy number and oxidative function between ER α -KO versus ER α -replete WAT and adipocytes. We showed that *Polg1*, the gene that encodes the catalytic subunit of the mtDNA polymerase γ POLG and is involved in the control of mtDNA replication, is reduced in ER α -KO versus ER α -replete white adipocytes. Although the reduction in tissue *Polg1* expression and consequent lipid accumulation was similar between ER α WAT (FERKO) and BAT (ER $\alpha\text{KO}^{\text{BAT}}$) knockout mice, the impact of ER α deletion on mtDNA copy number and mitophagic flux via parkin was divergent in the two different fat types. In contrast to the reduction in mtDNA copy number in ER α -deficient WAT, mtDNA copy number was maintained in BAT from ER $\alpha\text{KO}^{\text{BAT}}$ mice similarly to control.

In the context of ER α deletion, a reduction in mtDNA copy number occurred in both male and female mice. This observation is consistent with adipose tissue mtDNA reduction in rodent models of obesity and type 2 diabetes (46) and with our observations in subcutaneous adipose tissue from dysglycemic men. Consistent with the reduction in mtDNA copy number in ER α -deficient WAT, expression of the mtDNA polymerase *Polg1* and the mitochondrial RNA polymerase *Polrmt* as well as transcription factors associated with mitochondrial biogenesis markers *Pgc1b* and *Nrf1* were reduced. Similar to WAT, we also observed reductions in *Polg1* expression, mtDNA copy number, and genes associated with mitochondrial biogenesis markers in 3T3L1 adipocytes with *Esr1*-KD. As expected, cellular respiration and fatty acid oxidation rates were reduced in adipocytes lacking ER α , consistent with functional phenotypes previously observed in ER α -deficient muscle and myotubes (27). We confirmed that *Polg1* deletion could recapitulate the reduction in mtDNA copy number and increase mitophagic signaling in WAT. Although PINK1 and parkin protein content were elevated and the abundance of the mitochondrial fusion protein *Mfn2* was reduced in ER α -deficient white adipocytes, the molecular underpinnings driving these responses remain unclear, especially because mRNA expression of these markers was identical between FERKO and Control^{fl/fl}.

It has been suggested that a reduction in mitochondrial membrane potential initiates mitophagic signaling to eliminate mitochondrial contents from the network (27). This process is thought to require mitochondrial fission and separation of the organelle from the network. Because we detected a reduction in fission signaling in white adipocytes but no overt change in mitochondrial membrane potential, the signal coupling the reduction in *Esr1-Polg1* to mitophagic flux is not readily apparent. We did, however, detect increased variability in mitochondrial membrane potential on a cell-by-cell basis, which was recently suggested to reduce metabolic fitness (38). Thus, it is possible that a mitochondrial hetero-potential could serve as an underlying signal for mitochondrial turnover in white adipocytes.

We identified the mitochondrial stress sensor p53 as an intermediate signal linking parkin cellular redistribution with organelle turnover in *Esr1*-deficient adipocytes (47). Both p53 and parkin were coordinately recruited to mitochondria in *Esr1*-KD cells, and the reduction in the outer mitochondrial membrane target of parkin, *Mfn2*, supports enhanced parkin action to promote mitophagy. Increased mitophagy in *Esr1*-KD 3T3L1 adipocytes was also supported by confocal microscopy studies showing increased colocalization of mitochondria and lysosomes compared with ER α -replete cells. Overexpression of *Esr1* in adipocytes and chemical inhibition of p53

reduced parkin protein in mitochondrial fractions. These data are consistent with *in vivo* data, showing that p53 and parkin are increased in WAT of aged, HFD-fed, genetically obese, and insulin-resistant mice (33, 34, 36, 48) but reduced in metabolically fit animals and cells (49). These data suggest that ER α may control parkin action and mtDNA copy number by dictating the cellular localization of p53.

Here, we provide findings in adipose-selective Parkin KO mice (Parkin^{AdiKO}), and our observations are consistent with reports of global p53 and parkin deletion models showing reduced mitophagic flux, increased mtDNA content, and enhanced beige capacity of WAT (33, 49, 50). Moreover, p53^{KO}, Parkin^{KO}, and Parkin^{AdiKO} mouse models are phenotypically similar showing reduced fat accumulation when fed either a normal chow (NC) or HFD (34, 35, 37). Parkin-mediated mitophagy is selectively down-regulated during browning of WAT (49), and recent evidence shows that experimental parkin inhibition promotes fat beigeing while prolonging the retention of beige adipocytes even after β_3 -adrenergic receptor agonist withdrawal (43). These findings suggest that WAT beigeing observed during ER α agonism (26) may be underpinned by suppression of a p53-parkin axis to remodel and turnover the mitochondrial network. Our laboratory is currently interrogating whether overexpression of *Esr1* selectively in fat increases mitochondrial content and prevents HFD-induced increases in adiposity in male and female mice.

There exists a well-described sex difference in BAT abundance and activity in humans and rodents (23, 51, 52). Because females have higher BAT abundance and increased BAT activity, we examined whether *Esr1* plays a role in regulating BAT metabolism. *Esr1* was elevated in BAT of female mice, and the induction of *Ucp1* during cold exposure required the expression of *Esr1*. During cold exposure or norepinephrine treatment, mitochondria undergo rapid Drp1-induced fragmentation and increased respiration and utilization of fatty acids (16, 51, 53, 54). Accumulating evidence shows that mitochondrial fission signaling by Drp1 is an important initiator of adipocyte beigeing and browning (51, 54, 55). KD of Drp1 reduces *Ucp1* expression, blunts uncoupled mitochondrial respiration, shifts substrate metabolism to glucose, and is associated with BAT lipid droplet accumulation—all features recapitulated in ER α KO^{BAT} mice (51, 55). We have previously shown that ER α expression is intimately connected with Drp1 signaling and fission competency in skeletal muscle (27, 28). Our observations of impaired mitochondrial fission signaling but preservation of mtDNA copy number in ER α -deficient BAT is reminiscent of findings in ER α -deficient skeletal muscle (27). In view of the fact that muscle and BAT are derived from the same precursor lineage (56–58), it follows that the brown fat transcriptome and proteome are more similar to their counterparts in skeletal muscle than WAT (52). Collectively, our findings point to ER α -controlled mitochondrial remodeling via Drp1 as a central mechanism underlying the well-described sexual dimorphism in BAT abundance and activity.

Fission competency is also a requisite for mtDNA replication via *Polg1* (31). As we showed the direct regulation of *Polg1* expression by ER α in adipocytes, we presume that the marked reduction of *Polg1* expression in BAT of ER α KO^{BAT} mice is the consequence of reduced positive regulation by ER α . This finding is consistent with our previous studies in skeletal muscle, showing a direct role for ER α in the regulation of *Polg1* expression and mtDNA replication (27). Despite the reduction in *Polg1* expression in BAT of ER α KO^{BAT}, in contrast to FERKO, mtDNA copy number was equivalent in BAT

from ER α KO^{BAT} compared to Control^{l^{fl}} mice. We have observed that a mitochondrial fission–mtDNA replication axis exerts feedback control of macro- and micro-autophagy (27, 28). The rates of flux and the relative balance between mtDNA replication and mtDNA degradation govern mtDNA copy number (59, 60). In contrast to WAT, the preservation of mtDNA copy number in ER α -deficient BAT and skeletal muscle presumably occurred as a consequence of reduced flux in mitophagy to match diminished rates of mtDNA replication (27, 28). The molecular mechanisms controlling the health of the mitochondrial genome and whether copy number is a meaningful marker of mitochondrial function remain inadequately understood. In addition, retrograde signaling links between intramitochondrial events, such as mtDNA replication with changes in nuclear genes expression also require further investigation.

One limitation of the current investigation is a lack of balanced and comprehensive investigation in both sexes in humans and mice. In addition, the use of conventional Cre recombinase transgenic mouse lines introduced issues involving cell type specificity and adaptive phenotypes as a consequence of gene deletion during development. To circumvent developmental adaptations that arise due to gene deletion, we have now generated animals with conditional deletion alleles of *Esr1*, and studies in these mice are underway. We have also generated a mouse line conditionally overexpressing *Esr1* in WAT or BAT. We will use this mouse line to ascertain whether increasing *Esr1* expression in adipose tissue confers protection against diet-induced obesity and insulin resistance. In addition, in future research, we will perform metabolic caging studies to determine the role of adipose tissue *Esr1* in controlling whole-body energy homeostasis, as a lack of indirect calorimetry assessment in physiological samples is a major limitation of the current work.

Our research shows that *ESR1* is highly heritable, inversely associated with fat mass, and modulated in expression by environmental factors including caloric consumption, exercise, and temperature. The findings reported here support the notion that ER α regulates mitochondrial function and energy homeostasis in WAT and BAT via coordinated control of mtDNA replication by *Polg1* and fission-fusion-mitophagy dynamics. With respect to chronic disease susceptibility, reduced ER α action impairs mitochondrial function, promotes increased adiposity, and disrupts metabolic homeostasis in mice and humans. Therefore, ER α action in adipose tissue may be an attractive therapeutic target to combat obesity and metabolic dysfunction especially in women during the menopausal transition.

MATERIALS AND METHODS

Study design

The objectives of this research were to understand the role of ER α in the control of adiposity and to identify target genes that control mitochondrial function in white and brown adipocytes. First, to establish a clinical rationale for our studies in genetically engineered mice, we determined the relationship between adipose tissue *Esr1/ESR1* expression and clinical traits including fat mass and indices of metabolic function using historical deidentified data and samples from published human (29, 61–68) and mouse studies (6, 69). Each human participant provided written informed consent before participation, and the study procedures were approved by the Scientific Ethical Committees of the respective institutions in accordance with the principles of the Declaration of Helsinki. All procedures in rodents were performed in accordance with the Guide for the Care

and Use of Laboratory Animals of the National Institutes of Health (NIH) and were approved by the Animal Subjects Committee of UCLA.

We investigated adipose *ESR1* expression in dysglycemic subjects compared to lean healthy controls. To identify the mechanisms by which ER α controls adiposity, we generated mice with an adipose-selective ER α deletion using the standard Cre-Lox approach. We performed phenotypic evaluation of at least five cohorts of FERKO and Control^{fl/fl} mice using a variety of in vivo and ex vivo approaches. The number of animals used for each study was determined by power calculations using an a priori *P* value of <0.05; animal numbers for each study are indicated in the figure legends. All studies assessing glucose homeostasis were blinded for animal genotype. To study cells in culture, we generated primary fat cells from Control^{fl/fl}, FERKO, and Polg1^{fl/fl} mice, as well as 3T3L1 adipocytes with ER α KD using lentiviral containing shRNA targeting *Esr1*. Nearly all in vitro studies were performed with a minimum of three independent experiments in duplicate, as indicated in figure legends.

Human studies analyzed

All data from human participants were generated from tissue samples obtained from previously published studies as reported below. No new human samples were acquired for the generation of this manuscript.

MyoGlu

Twenty-six sedentary (<1 exercise session/week) men of Scandinavian origin from Oslo, Norway (aged 40 to 65 years) were recruited into the Skeletal Muscles, Myokines, and Glucose Metabolism (MyoGlu) intervention trial and divided into two groups: (i) normoglycemic (NG control) with body mass index (BMI) of <27 kg/m² (*n* = 13) or (ii) dysglycemic (DG) with a BMI of 27 to 32 kg/m² with impaired fasting plasma glucose, impaired glucose tolerance (IGT), or insulin resistance (HOMA-IR) (*n* = 13), as described previously (62–65). Total adipose tissue, subcutaneous adipose tissue, and intra-abdominal adipose tissue were measured by magnetic resonance imaging (MRI) scanning (1.5T Philips Achieva MR, Philips) 3 weeks before and 2 weeks after a 12-week intensive exercise intervention (66). Subcutaneous abdominal adipose tissue samples (*n* = 48) were obtained 1 hour after an acute bicycle test, before and after training. The MyoGlu trial is registered at ClinicalTrials.gov (NCT01803568).

TwinsUK

We determined narrow sense heritability (*h*²) of *ESR1* in adipose tissue by accessing data from the TwinsUK study in which subcutaneous adipose tissue from punch biopsies (8 mm) were obtained adjacent and inferior to the umbilicus in ~766 healthy female monozygotic and dizygotic twins ages 38 to 85 years (median age of 62, ~75% postmenopausal by the final menstrual period calculation) (29, 61). Biopsies were RNA-sequenced as described (70), and correlations between adipose tissue expression of *ESR1* and metabolic traits were determined. TwinsUK RNA-seq data are available from the European Genome-phenome Archive (accession EGAS00001000805).

Metabolic Syndrome in Men

For the study of adipose tissue insulin sensitivity (study 1), 8460 nondiabetic participants from an ongoing population-based cross-sectional METSIM study were included (67, 68). In this previous study, participants aged 45 to 70 years were randomly selected from the population register of Kuopio, Eastern Finland. Of those included, 2951 participants had normal glucose tolerance, 4181 had isolated

impaired fasting glucose (IFG), 302 had isolated IGT, and 1026 had IFG and IGT according to the American Diabetes Association criteria. For the genetic association study (study 2), the first 6733 nondiabetic men (age 57.0 ± 6.9 years, BMI 26.8 ± 3.8 kg/m²; means ± SD) examined in the METSIM study were included. The gene expression study (study 3) included 41 obese participants (age 44.2 ± 8.3 years, BMI 45.5 ± 6.1 kg/m²) and 18 patients with type 2 diabetes from an ongoing study, including participants undergoing bariatric surgery at the Kuopio University Hospital. All studies were approved by the ethics committee of the University of Kuopio and Kuopio University Hospital and were carried out in accordance with the Declaration of Helsinki. Tissue-specific expression data were obtained from GeneSapiens, version IST4, containing expression data of 16 adipose tissue samples from healthy human tissue, measured with Affymetrix gene expression microarrays. METSIM adipose array data are available from Gene Expression Omnibus (GSE70353) (68). Gene-trait relationships presented here were obtained from 770 male participants.

Animals

Hybrid Mouse Diversity Panel

All mice were obtained from The Jackson Laboratory and bred at UCLA. Mice were maintained on a chow diet (PicoLab Rodent Diet 20, LabDiet, 62% carbohydrate, 13% fat, and 25% protein) until 8 weeks of age when they either continued on the chow diet or received a high-fat/high-sucrose diet (HF/HS Research Diets; 8 weeks, 16.8% kcal protein, 51.4% kcal carbohydrate, and 31.8% kcal fat). A complete list of the strains included in this study is in table S4. Gene symbols from HMDP mice were converted to human orthologs using biomaRt package (version 2.38.0) in R Studio.

Genetically engineered mice

ER α floxed mice (from K.S.K.) were crossed with adiponectin (a gift from E. Rosen) or UCP1 Cre mice (The Jackson Laboratory) to generate animals with ER α deletion in either white and brown fat or BAT selectively (fig. S1E). We selected these two conventional Cre lines to induce gene deletion during development because we are interested in understanding the impact of *Esr1* heritability and its relationship with metabolic health. Whole-body parkin null mice (The Jackson Laboratory) and adipose tissue-selective parkin knockout mice (Parkin^{AdiKO}), generated by crossing the parkin floxed line (floxed *parkin* mice were a gift from T. Dawson) with adiponectin Cre transgenic mice, were used to confirm a role for parkin in mediating the effects of ER α deletion on mtDNA copy number. Floxed *Polg1* mice were obtained from J.W. Mice were studied under NC-fed and HFD-fed conditions between the ages of 4 and 10 months. Mouse sex is indicated in the figure legends for each experiment.

Genetically engineered adipocytes and treatments

Isolated primary white adipose stromal vascular fraction cells from iWAT of *Polg1*-floxed mice were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium with 10% fetal bovine serum (FBS) as described (8, 71). Then, the cells were cultured for 2 days in DM1 medium [DMEM/F12 medium, 10% FBS, insulin (5 μ g/ml), 1 μ M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 1 μ M rosiglitazone], 2 days in DM2 medium [DMEM/F12 medium with 10% FBS and insulin (5 μ g/ml)], and extra 6 days in DM2 medium. To achieve *Esr1* KD, lentiviral particles (sc-37776-V, Santa Cruz Biotechnology) carrying shRNA targeted to *Esr1* or scramble shRNA (multiplicity of infection = 3) were used to transduce 3T3L1 preadipocytes. Forty-eight hours after transduction, the cells were analyzed for KD efficiency by immunoblotting and reverse transcription

polymerase chain reaction (RT-PCR). To achieve *Polg1*-KD, 1.2×10^{10} genome copies (GC) of AAV8-CMV-GFP (green fluorescent protein) and AAV8-CMV-Cre-GFP (7061 and 7062, Vector Biolabs) were used to transduce primary adipocytes for 6 days. Cells were analyzed for KD efficiency and mtDNA copy number by RT-PCR as described below. In studies to assess membrane potential, cells were labeled with MTG (Invitrogen) and TMRE (Invitrogen). Fluorescence was quantified by confocal microscopy and analyzed in Fiji (ImageJ, NIH) as described below (38).

Statistical analysis

Values are presented as means \pm SEM and expressed relative to the respective control group. Group differences were assessed by Student's *t* test, one-way analysis of variance (ANOVA), or two-way ANOVA where appropriate followed by Tukey's post hoc test. Data were tested for normality before the use of a parametric test. Venn diagrams were created using the VennDiagram package (version 1.6.20) in R Studio. Gene overlaps presented in Fig. 1K *ESR1/Esr1* by gene correlations were calculated in adipose tissue from METSIM, MyoGlu, and HMDD studies using the midweight bicorrelation function in the weighted gene correlation network analysis package (version 1.67) in R Studio; significant correlations were set a priori as $P < 0.001$. Statistical significance of overlap for Venn diagrams was determined for each pairwise overlap using the hypergeometric probability formula. The representation factor (RF) indicates the fold change in observed versus expected overlap (R package version 1.24.0) (72). Statistical significance was established a priori at $P < 0.05$ for all other comparisons (GraphPad Prism 7.0).

SUPPLEMENTARY MATERIALS

stm.sciencemag.org/cgi/content/full/12/555/eaax8096/DC1

Materials and methods

Fig. S1. Overview of the human and mouse studies included in this investigation.

Fig. S2. Characteristics of male and female FERKO mice.

Fig. S3. Expression analyses performed on adipose tissue samples from men participating in the MyoGlu studies.

Fig. S4. The impact of *Esr1* loss and gain of expression on parkin and p53 cellular localization.

Fig. S5. Mitochondrial membrane potential in 3T3L1 adipocytes in the presence or absence of *Esr1*.

Fig. S6. ER α protein expression in gonadal and inguinal adipose tissue of BAT-specific ER α KO mice (ER α KO^{BAT}).

Fig. S7. LC3B expression is reduced in BAT from ER α KO^{BAT} mice.

Fig. S8. Schematic overview of the mechanisms by which ER α controls adipocyte metabolism and adiposity.

Table S1. Genes significantly correlated with *ESR1/Esr1* and overlapping between the METSIM, MyoGlu, and HMDD studies.

Table S2. Genes associated with *Esr1* in gWAT from male and female C57BL/6J mice.

Table S3. Mitochondrial-associated genes differentially expressed in gWAT from female FERKO versus Control^{fl/fl} mice.

Table S4. Mouse strains studied from the UCLA HMDDP.

Table S5. qPCR primers used to assess gene expression in adipose tissue from WT C57BL/6J, *Esr1* Control^{fl/fl}, FERKO, and ER α KO^{BAT} mice.

Table S6. qPCR primers used for ChIP studies to assess the binding of ER α to the *Polg1* proximal promoter in 3T3L1 adipocytes.

Data file S1. Raw data from studies of human tissues, cells, and genetically engineered mice.

Data file S2. Raw data of *ESR1*-correlated genes in subcutaneous fat from men participating in the METSIM study.

Data file S3. Raw data of *ESR1*-correlated genes in subcutaneous fat from men participating in the MyoGlu study.

Data file S4. Raw data of *Esr1*-correlated genes in gonadal fat from male mice of the UCLA HMDDP.

Data file S5. Raw data of *Esr1*-correlated genes in gonadal fat from female mice of the UCLA HMDDP.

Data file S6. GO of microarray data performed on gonadal fat from female FERKO and Control^{fl/fl} mice.

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. A. Kautzky-Willer, J. Harreiter, G. Pacini, Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. *Endocr. Rev.* **37**, 278–316 (2016).
2. G. A. Greendale, B. Sternfeld, M. Huang, W. Han, C. Karvonen-Gutierrez, K. Ruppert, J. A. Cauley, J. S. Finkelstein, S. F. Jiang, A. S. Karlamangla, Changes in body composition and weight during the menopause transition. *JCI Insight* **4**, e124865 (2019).
3. S. Heinonen, M. Muniandy, J. Buzkova, A. Mardinoglu, A. Rodriguez, G. Fruhbeck, A. Hakkarainen, J. Lundbom, N. Lundbom, J. Kaprio, A. Rissanen, K. H. Pietilainen, Mitochondria-related transcriptional signature is downregulated in adipocytes in obesity: A study of young healthy MZ twins. *Diabetologia* **60**, 169–181 (2017).
4. X. Yin, I. R. Lanza, J. M. Swain, M. G. Sarr, K. S. Nair, M. D. Jensen, Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. *J. Clin. Endocrinol. Metab.* **99**, E209–E216 (2014).
5. R. Zamora-Mendoza, H. Rosas-Vargas, M. T. Ramos-Cervantes, P. Garcia-Zuniga, H. Perez-Lorenzana, P. Mendoza-Lorenzo, A. C. Perez-Ortiz, F. J. Estrada-Mena, A. Millar-Garcia, E. Lara-Padilla, G. Ceballos, A. Rodriguez, F. Villarreal, I. Ramirez-Sanchez, Dysregulation of mitochondrial function and biogenesis modulators in adipose tissue of obese children. *Int. J. Obes. (Lond)* **42**, 618–624 (2018).
6. F. Norheim, Y. Hasin-Brumshtein, L. Vergnes, K. Chella Krishnan, C. Pan, M. M. Seldin, S. T. Hui, M. Mehrabian, Z. Zhou, S. Gupta, B. W. Parks, A. Walch, K. Reue, S. M. Hofmann, A. P. Arnold, A. J. Lusis, Gene-by-sex interactions in mitochondrial functions and cardio-metabolic traits. *Cell Metab.* **29**, 932–949.e4 (2019).
7. M. Nilsson, I. Dahlman, M. Ryden, E. A. Nordstrom, J. A. Gustafsson, P. Arner, K. Dahlman-Wright, Oestrogen receptor alpha gene expression levels are reduced in obese compared to normal weight females. *Int. J. Obes.* **31**, 900–907 (2007).
8. B. G. Drew, H. Hamidi, Z. Zhou, C. J. Villanueva, S. A. Krum, A. C. Calkin, B. W. Parks, V. Ribas, N. Y. Kalajian, J. Phun, P. Daraei, H. R. Christofk, S. C. Hewitt, K. S. Korach, P. Tontonoz, A. J. Lusis, D. J. Slamon, S. A. Hurvitz, A. L. Hevener, Estrogen receptor (ER) α -regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. *J. Biol. Chem.* **290**, 5566–5581 (2015).
9. D. Ricquier, J. C. Kader, Mitochondrial protein alteration in active brown fat: A soidum dodecyl sulfate-polyacrylamide gel electrophoretic study. *Biochem. Biophys. Res. Commun.* **73**, 577–583 (1976).
10. M. Hibi, S. Oishi, M. Matsushita, T. Yoneshiro, T. Yamaguchi, C. Usui, K. Yasunaga, Y. Katsuragi, K. Kubota, S. Tanaka, M. Saito, Brown adipose tissue is involved in diet-induced thermogenesis and whole-body fat utilization in healthy humans. *Int. J. Obes.* **40**, 1655–1661 (2016).
11. M. Klingenberg, UCP1 - A sophisticated energy valve. *Biochimie* **134**, 19–27 (2017).
12. A. A. van der Lans, J. Hoeks, B. Brans, G. H. Vijgen, M. G. Visser, M. J. Vosselman, J. Hansen, J. A. Jorgensen, J. Wu, F. M. Mottaghy, P. Schrauwen, W. D. van Marken Lichtenbelt, Cold acclimation recruits human brown fat and increases nonshivering thermogenesis. *J. Clin. Invest.* **123**, 3395–3403 (2013).
13. J. Nedergaard, V. Golozoubova, A. Matthias, A. Asadi, A. Jacobsson, B. Cannon, UCP1: The only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. *Biochim. Biophys. Acta* **1504**, 82–106 (2001).
14. J. Nedergaard, V. Golozoubova, A. Matthias, I. Shabalina, K. Ohba, K. Ohlson, A. Jacobsson, B. Cannon, Life without UCP1: Mitochondrial, cellular and organismal characteristics of the UCP1-ablated mice. *Biochem. Soc. Trans.* **29**, 756–763 (2001).
15. V. Golozoubova, E. Hohtola, A. Matthias, A. Jacobsson, B. Cannon, J. Nedergaard, Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold. *FASEB J.* **15**, 2048–2050 (2001).
16. M. Calderon-Dominguez, J. F. Mir, R. Fucho, M. Weber, D. Serra, L. Herrero, Fatty acid metabolism and the basis of brown adipose tissue function. *Adipocyte* **5**, 98–118 (2016).
17. A. Bartelt, J. Heeren, Adipose tissue browning and metabolic health. *Nat. Rev. Endocrinol.* **10**, 24–36 (2014).
18. C. Scheele, S. Nielsen, Metabolic regulation and the anti-obesity perspectives of human brown fat. *Redox Biol.* **12**, 770–775 (2017).
19. V. Peirce, A. Vidal-Puig, Regulation of glucose homeostasis by brown adipose tissue. *Lancet Diabetes Endocrinol.* **1**, 353–360 (2013).
20. R. Fernandez-Verdejo, K. L. Marlatt, E. Ravussin, J. E. Galgani, Contribution of brown adipose tissue to human energy metabolism. *Mol. Aspects Med.* **68**, 82–89 (2019).
21. S. Kajimura, B. M. Spiegelman, P. Seale, Brown and beige fat: Physiological roles beyond heat generation. *Cell Metab.* **22**, 546–559 (2015).
22. K. Klepac, A. Georgiadi, M. Tschop, S. Herzig, The role of brown and beige adipose tissue in glycaemic control. *Mol. Aspects Med.* **68**, 90–100 (2019).
23. A. M. Cypess, S. Lehman, G. Williams, I. Tal, D. Rodman, A. B. Goldfine, F. C. Kuo, E. L. Palmer, Y. H. Tseng, A. Doria, G. M. Kolodny, C. R. Kahn, Identification and importance of brown adipose tissue in adult humans. *N. Engl. J. Med.* **360**, 1509–1517 (2009).
24. J. C. van den Beukel, A. Grefhorst, M. J. Hoogduijn, J. Steenbergen, P. G. Mastroberardino, F. J. Dor, A. P. Themmen, Women have more potential to induce browning of perirenal adipose tissue than men. *Obesity (Silver Spring)* **23**, 1671–1679 (2015).

25. S. M. Al-Qahtani, G. Bryzgalova, I. Valladolid-Acebes, M. Korach-Andre, K. Dahlman-Wright, S. Efendic, P. O. Berggren, N. Portwood, 17 β -Estradiol suppresses visceral adipogenesis and activates brown adipose tissue-specific gene expression. *Horm. Mol. Biol. Clin. Investig.* **29**, 13–26 (2017).
26. R. S. Santos, A. P. Frank, L. A. Fatima, B. F. Palmer, O. K. Oz, D. J. Clegg, Activation of estrogen receptor alpha induces beiging of adipocytes. *Mol. Metab.* **18**, 51–59 (2018).
27. V. Ribas, B. G. Drew, Z. Zhou, J. Phun, N. Y. Kalajian, T. Soleymani, P. Daraei, K. Widjaja, J. Wanagat, T. Q. de Aguiar Vallim, A. H. Fluitt, S. Bensinger, T. Le, C. Radu, J. P. Whitelegge, S. W. Beaven, P. Tontonoz, A. J. Lusis, B. W. Parks, L. Vergnes, K. Reue, H. Singh, J. C. Bopassa, L. Toro, E. Stefani, M. J. Watt, S. Schenk, T. Akerstrom, M. Kelly, B. K. Pedersen, S. C. Hewitt, K. S. Korach, A. L. Hevener, Skeletal muscle action of estrogen receptor alpha is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. *Sci. Transl. Med.* **8**, 334ra354 (2016).
28. Z. Zhou, V. Ribas, P. Rajbhandari, B. G. Drew, T. M. Moore, A. H. Fluitt, B. R. Reddish, K. A. Whitney, S. Georgia, L. Vergnes, K. Reue, M. Liesa, O. Shirihai, A. M. van der Blik, N. W. Chi, S. K. Mahata, J. P. Tian, S. C. Hewitt, P. Tontonoz, K. S. Korach, F. Mauvais-Jarvis, A. L. Hevener, Estrogen receptor α protects pancreatic β -cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. *J. Biol. Chem.* **293**, 4735–4751 (2018).
29. E. Grundberg, K. S. Small, A. K. Hedman, A. C. Nica, A. Buil, S. Keildson, J. T. Bell, T. P. Yang, E. Meduri, A. Barrett, J. Nisbett, M. Sekowska, A. Wilk, S. Y. Shin, D. Glass, M. Travers, J. L. Min, S. Ring, K. Ho, G. Thorleifsson, A. Kong, U. Thorsteinsdottir, C. Ainali, A. S. Dimas, N. Hassanali, C. Ingle, D. Knowles, M. Krestyaninova, C. E. Lowe, P. Di Meglio, S. B. Montgomery, L. Parts, S. Potter, G. Surdulescu, L. Tsaprouni, S. Tsoka, V. Bataille, R. Durbin, F. O. Nestle, S. O'Rahilly, N. Soranzo, C. M. Lindgren, K. T. Zondervan, K. R. Ahmadi, E. E. Schadt, K. Stefansson, G. D. Smith, M. I. McCarthy, P. Deloukas, E. T. Dermizakis, T. D. Spector; Multiple Tissue Human Expression Resource, Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nat. Genet.* **44**, 1084–1089 (2012).
30. A. Lindinger, R. Peterli, T. Peters, B. Kern, M. von Flue, M. Calame, M. Hoch, A. N. Eberle, P. W. Lindinger, Mitochondrial DNA content in human omental adipose tissue. *Obes. Surg.* **20**, 84–92 (2010).
31. S. C. Lewis, L. F. Uchiyama, J. Nunnari, ER-mitochondria contacts couple mtDNA synthesis with mitochondrial division in human cells. *Science* **353**, aaf5549 (2016).
32. A. Hoshino, M. Ariyoshi, Y. Okawa, S. Kaimoto, M. Uchihashi, K. Fukai, E. Iwai-Kanai, K. Ikeda, T. Ueyama, T. Ogata, S. Matoba, Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic β -cell function in diabetes. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 3116–3121 (2014).
33. W. Fu, Y. Liu, C. Sun, H. Yin, Transient p53 inhibition sensitizes aged white adipose tissue for beige adipocyte recruitment by blocking mitophagy. *FASEB J.* **33**, 844–856 (2018).
34. T. Minamino, M. Orimo, I. Shimizu, T. Kunieda, M. Yokoyama, T. Ito, A. Nojima, A. Nabetani, Y. Oike, H. Matsubara, F. Ishikawa, I. Komuro, A crucial role for adipose tissue p53 in the regulation of insulin resistance. *Nat. Med.* **15**, 1082–1087 (2009).
35. J. Krstic, I. Reinisch, M. Schupp, T. J. Schulz, A. Prokesch, p53 functions in adipose tissue metabolism and homeostasis. *Int. J. Mol. Sci.* **19**, 2622 (2018).
36. I. Shimizu, Y. Yoshida, T. Katsuno, K. Tateno, S. Okada, J. Moriya, M. Yokoyama, A. Nojima, T. Ito, R. Zechner, I. Komuro, Y. Kobayashi, T. Minamino, p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. *Cell Metab.* **15**, 51–64 (2012).
37. K. Y. Kim, M. V. Stevens, M. H. Akter, S. E. Rusk, R. J. Huang, A. Cohen, A. Noguchi, D. Springer, A. V. Bocharov, T. L. Eggerman, D. F. Suen, R. J. Youle, M. Amar, A. T. Remaley, M. N. Sack, Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. *J. Clin. Invest.* **121**, 3701–3712 (2011).
38. D. M. Wolf, M. Segawa, A. K. Kondadi, R. Anand, S. T. Bailey, A. S. Reichert, A. M. van der Blik, D. B. Shackelford, M. Liesa, O. S. Shirihai, Individual cristae within the same mitochondrion display different membrane potentials and are functionally independent. *EMBO J.* **38**, e101056 (2019).
39. S. M. Jin, M. Lazarou, C. Wang, L. A. Kane, D. P. Narendra, R. J. Youle, Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J. Cell Biol.* **191**, 933–942 (2010).
40. D. P. Narendra, S. M. Jin, A. Tanaka, D. F. Suen, C. A. Gautier, J. Shen, M. R. Cookson, R. J. Youle, PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol.* **8**, e1000298 (2010).
41. I. Martinez-Reyes, L. P. Diebold, H. Kong, M. Schieber, H. Huang, C. T. Hensley, M. M. Mehta, T. Wang, J. H. Santos, R. Woychik, E. Dufour, J. N. Spellbrink, S. E. Weinberg, Y. Zhao, R. J. DeBerardinis, N. S. Chandel, TCA cycle and mitochondrial membrane potential are necessary for diverse biological functions. *Mol. Cell* **61**, 199–209 (2016).
42. X. Kong, A. Banks, T. Liu, L. Zakak, R. R. Rao, P. Cohen, X. Wang, S. Yu, J. C. Lo, Y. H. Tseng, A. M. Cypess, R. Xue, S. Kleiner, S. Kang, B. M. Spiegelman, E. D. Rosen, IRF4 is a key thermogenic transcriptional partner of PGC-1 α . *Cell* **158**, 69–83 (2014).
43. X. Lu, S. Altshuler-Keylin, Q. Wang, Y. Chen, C. Henrique Sponton, K. Ikeda, P. Maretich, T. Yonshiro, S. Kajimura, Mitophagy controls beige adipocyte maintenance through a Parkin-dependent and UCP1-independent mechanism. *Sci. Signal.* **11**, eaap8526 (2018).
44. E. Gonzalez-Hurtado, J. Lee, J. Choi, M. J. Wolfgang, Fatty acid oxidation is required for active and quiescent brown adipose tissue maintenance and thermogenic programming. *Mol Metab* **7**, 45–56 (2018).
45. V. Ribas, M. T. Nguyen, D. C. Henstridge, A. K. Nguyen, S. W. Beaven, M. J. Watt, A. L. Hevener, Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. *Am. J. Physiol. Endocrinol. Metab.* **298**, E304–E319 (2010).
46. H. J. Choo, J. H. Kim, O. B. Kwon, C. S. Lee, J. Y. Mun, S. S. Han, Y. S. Yoon, G. Yoon, K. M. Choi, Y. G. Ko, Mitochondria are impaired in the adipocytes of type 2 diabetic mice. *Diabetologia* **49**, 784–791 (2006).
47. S. D. Konduri, R. Medisetty, W. Liu, B. A. Kaiparettu, P. Srivastava, H. Brauch, P. Fritz, W. M. Swetzig, A. E. Gardner, S. A. Khan, G. M. Das, Mechanisms of estrogen receptor antagonist toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 15081–15086 (2010).
48. N. Yahagi, H. Shimano, T. Matsuzaka, Y. Najima, M. Sekiya, Y. Nakagawa, T. Ide, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, T. Gotoda, R. Nagai, S. Kimura, S. Ishibashi, J. Osuga, N. Yamada, p53 Activation in adipocytes of obese mice. *J. Biol. Chem.* **278**, 25395–25400 (2003).
49. D. Taylor, R. A. Gottlieb, Parkin-mediated mitophagy is downregulated in browning of white adipose tissue. *Obesity (Silver Spring)* **25**, 704–712 (2017).
50. J. Naukkarinen, S. Heinonen, A. Hakkarainen, J. Lundbom, K. Vuolteenaho, L. Saarinen, S. Hautaniemi, A. Rodriguez, G. Fruhbeck, P. Pajunen, T. Hyotylinen, M. Oresic, E. Moolanen, A. Suomalainen, N. Lundbom, J. Kaprio, A. Rissanen, K. H. Pietilainen, Characterising metabolically healthy obesity in weight-discordant monozygotic twins. *Diabetologia* **57**, 167–176 (2014).
51. D. F. Pisani, V. Barquissau, J. C. Chambard, D. Beuzelin, R. A. Ghandour, M. Giroud, A. Mairal, S. Pagnotta, S. Cinti, D. Langin, E. Z. Amri, Mitochondrial fission is associated with UCP1 activity in human brite/beige adipocytes. *Mol. Metab.* **7**, 35–44 (2018).
52. F. Forner, C. Kumar, C. A. Luber, T. Fromme, M. Klingenspor, M. Mann, Proteome differences between brown and white fat mitochondria reveal specialized metabolic functions. *Cell Metab.* **10**, 324–335 (2009).
53. V. Barquissau, D. Beuzelin, D. F. Pisani, G. E. Beranger, A. Mairal, A. Montagner, B. Roussel, G. Tavernier, M. A. Marques, C. Moro, H. Guillou, E. Z. Amri, D. Langin, White-to-brite conversion in human adipocytes promotes metabolic reprogramming towards fatty acid anabolic and catabolic pathways. *Mol. Metab.* **5**, 352–365 (2016).
54. J. D. Wikstrom, K. Mahdavian, M. Liesa, S. B. Sereda, Y. Si, G. Las, G. Twig, N. Petrovic, C. Zingaretti, A. Graham, S. Cinti, B. E. Corkey, B. Cannon, J. Nedergaard, O. S. Shirihai, Hormone-induced mitochondrial fission is utilized by brown adipocytes as an amplification pathway for energy expenditure. *EMBO J.* **33**, 418–436 (2014).
55. K. Mahdavian, I. Y. Benador, S. Su, R. A. Gharakhanian, L. Stiles, K. M. Trudeau, M. Cardamone, V. Enriquez-Zarralanga, E. Ritou, T. Aprahamian, M. F. Oliveira, B. E. Corkey, V. Perissi, M. Liesa, O. S. Shirihai, Mfn2 deletion in brown adipose tissue protects from insulin resistance and impairs thermogenesis. *EMBO Rep.* **18**, 1123–1138 (2017).
56. J. A. Timmons, K. Wennmalm, O. Larsson, T. B. Walden, T. Lassmann, N. Petrovic, D. L. Hamilton, R. E. Gimeno, C. Wahlestedt, K. Baar, J. Nedergaard, B. Cannon, Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 4401–4406 (2007).
57. S. Kajimura, P. Seale, K. Kubota, E. Lunsford, J. V. Frangioni, S. P. Gygi, B. M. Spiegelman, Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. *Nature* **460**, 1154–1158 (2009).
58. P. Seale, S. Kajimura, B. M. Spiegelman, Transcriptional control of brown adipocyte development and physiological function—of mice and men. *Genes Dev.* **23**, 788–797 (2009).
59. G. Twig, B. Hyde, O. S. Shirihai, Mitochondrial fusion, fission and autophagy as a quality control axis: The bioenergetic view. *Biochim. Biophys. Acta* **1777**, 1092–1097 (2008).
60. G. Twig, A. Elorza, A. J. Molina, H. Mohamed, J. D. Wikstrom, G. Walzer, L. Stiles, S. E. Haigh, S. Katz, G. Las, J. A. L. Aloy, M. Wu, B. F. Py, J. Yuan, J. T. Deeney, B. E. Corkey, O. S. Shirihai, Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *EMBO J.* **27**, 433–446 (2008).
61. C. A. Glastonbury, A. Vinuela, A. Buil, G. H. Halldorsson, G. Thorleifsson, H. Helgason, U. Thorsteinsdottir, K. Stefansson, E. T. Dermizakis, T. D. Spector, K. S. Small, Adiposity-dependent regulatory effects on multi-tissue transcriptomes. *Am. J. Hum. Genet.* **99**, 567–579 (2016).
62. S. Lee, F. Norheim, H. L. Gulseth, T. M. Langleite, A. Aker, T. E. Gundersen, T. Holen, K. I. Birkeland, C. A. Drevon, Skeletal muscle phosphatidylcholine and phosphatidylethanolamine respond to exercise and influence insulin sensitivity in men. *Sci. Rep.* **8**, 6531 (2018).

63. Y. Li, S. Lee, T. Langleite, F. Norheim, S. Pourteymour, J. Jensen, H. K. Stadheim, T. H. Storas, S. Davanger, H. L. Gulseth, K. I. Birkeland, C. A. Drevon, T. Holen, Subsarcolemmal lipid droplet responses to a combined endurance and strength exercise intervention. *Physiol. Rep.* **2**, e12187 (2014).
64. T. M. Langleite, J. Jensen, F. Norheim, H. L. Gulseth, D. S. Tangen, K. J. Kolnes, A. Heck, T. Storas, G. Grothe, M. A. Dahl, A. Kielland, T. Holen, H. J. Noreng, H. K. Stadheim, A. Bjornerud, E. I. Johansen, B. Nellemann, K. I. Birkeland, C. A. Drevon, Insulin sensitivity, body composition and adipose depots following 12 w combined endurance and strength training in dysglycemic and normoglycemic sedentary men. *Arch. Physiol. Biochem.* **122**, 167–179 (2016).
65. F. Norheim, T. M. Langleite, M. Hjorth, T. Holen, A. Kielland, H. K. Stadheim, H. L. Gulseth, K. I. Birkeland, J. Jensen, C. A. Drevon, The effects of acute and chronic exercise on PGC-1 α , irisin and browning of subcutaneous adipose tissue in humans. *FEBS J.* **281**, 739–749 (2014).
66. C. Sommer, S. Lee, H. L. Gulseth, J. Jensen, C. A. Drevon, K. I. Birkeland, Soluble leptin receptor predicts insulin sensitivity and correlates with upregulation of metabolic pathways in men. *J. Clin. Endocrinol. Metab.* **103**, 1024–1032 (2018).
67. L. D. Orozco, C. Farrell, C. Hale, L. Rubbi, A. Rinaldi, M. Civelek, C. Pan, L. Lam, D. Montoya, C. Edillor, M. Seldin, M. Boehnke, K. L. Mohlke, S. Jacobsen, J. Kuusisto, M. Laakso, A. J. Lusis, M. Pellegrini, Epigenome-wide association in adipose tissue from the METSIM cohort. *Hum. Mol. Genet.* **27**, 1830–1846 (2018).
68. J. Vangipurapu, A. Stancakova, J. Pihlajamaki, T. M. Kuulasmaa, T. Kuulasmaa, J. Paananen, J. Kuusisto, E. Ferrannini, M. Laakso, Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. *Diabetologia* **54**, 563–571 (2011).
69. B. W. Parks, T. Sallam, M. Mehrabian, N. Psychogios, S. T. Hui, F. Norheim, L. W. Castellani, C. D. Rau, C. Pan, J. Phun, Z. Zhou, W. P. Yang, I. Neuhaus, P. S. Gargalovic, T. G. Kirchgessner, M. Graham, R. Lee, P. Tontonoz, R. E. Gerszten, A. L. Hevener, A. J. Lusis, Genetic architecture of insulin resistance in the mouse. *Cell Metab.* **21**, 334–347 (2015).
70. A. Buil, A. A. Brown, T. Lappalainen, A. Vinuela, M. N. Davies, H. F. Zheng, J. B. Richards, D. Glass, K. S. Small, R. Durbin, T. D. Spector, E. T. Dermitzakis, Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. *Nat. Genet.* **47**, 88–91 (2015).
71. C. J. Villanueva, H. Waki, C. Godio, R. Nielsen, W. L. Chou, L. Vargas, K. Wroblewski, C. Schmedt, L. C. Chao, R. Boyadjian, S. Mandrup, A. Hevener, E. Saez, P. Tontonoz, TLE3 is a dual-function transcriptional coregulator of adipogenesis. *Cell Metab.* **13**, 413–427 (2011).
72. J. Amand, T. Fehlmann, C. Backes, A. Keller, DynaVenn: Web-based computation of the most significant overlap between ordered sets. *BMC Bioinformatics* **20**, 743 (2019).

Acknowledgments: We would like to thank K. I. Birkeland (Oslo University Diabetes Research Centre) and C. Pan (UCLA Department of Human Genetics) for assisting in data collection and reduction and the UCLA Division of Laboratory Animal Medicine for assisting with animal husbandry and welfare. **Funding:** This research was supported by funding to A.L.H. from the UCLA Department of Medicine, the Iris Cantor-UCLA Women's Health Center Research

Foundation and UCLA CTSI (ULTR000124), the UCLA Claude D. Pepper Older Americans Independence Center, and the NIH (DK109724, P30DK063491, and NURSA NDSP under parent award U24DK097748). Z.Z. was supported by the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute of Aging (5P30AG028748), the NIH/NCATS UCLA CTSI Grant (UL1TR000124), and the UCLA Center for Duchenne Muscular Dystrophy-NIH NIAMS (U54 AR052646) Wellstone Center of Excellence Training. T.M.M. was supported by a Kirschstein-NRSA predoctoral fellowship (F31DK108657), a Carl V. Gisolfi Memorial Research grant from the American College of Sports Medicine, and a predoctoral graduate student award from the Dornsife College at the University of Southern California. S.K.M. was supported by a grant from the Department of Veterans Affairs (I01BX000323). K.S.K. was supported by the NIEHS Division of Intramural Research 1ZIAES070065. A.J.L. was supported by NIH grants HL28481 and HL30568. K.R., A.J.L., and A.L.H. are collaboratively supported by an NIH SCORE on Sex Differences and Women's Health (U54DK120342). **Author contributions:** A.L.H., Z.Z., T.M.M., J.L., M.M.S., K.S.S., P.T., A.J.L., O.S., K.S.K., S.L., K.R., F.N., and J.W. conceived and designed the experiments. C.G. and K.S.S. performed the studies and informatics analyses associated with the TwinsUK studies. M.L. and M.C. provided data from the METSIM studies. S.L., J.J., F.N., and C.A.D. performed the MyoGlu studies. K.S.K. and S.C.H. generated the floxed *Esr1* mouse. F.N., T.M.M., M.M.S., Z.Z., and A.J.L. were involved in tissue collection and bioinformatic analysis associated with the HMDP studies. A.L.H., Z.Z., T.M.M., E.L., V.R., K.A.W., A.R.S., and B.R.R. performed in vivo studies in FERKO, *Er α KO^{BAT}*, *Parkin^{KO}*, and *Parkin^{A^{del}KO}* mice and ex vivo studies on tissues from genetically engineered animals. J.W. generated the floxed *Polg1* mice and helped Z.Z. with studies of mtDNA copy number. Z.Z. and B.G.D. performed all adipocyte culture studies. L.V., K.R., M.S., D.M.W., and O.S. executed studies related to mitochondrial respirometry and confocal microscopy. S.K.M. conducted the electron microscopy studies. Z.Z., P.R., and P.T. executed the ChIP studies in adipocytes. Z.Z. and J.L. performed all PET imaging studies. Z.Z. and B.G.D. performed all thermotolerance studies. Z.Z., T.M.M., V.R., P.R., B.G.D., M.C., K.A.W., L.V., D.M.W., M.S., S.K.M., S.C.H., S.L., K.S.S., M.L., S.L., M.M.S., and F.N. analyzed the data. Z.Z., B.G.D., C.A.D., O.S., K.S.K., A.J.L., and A.L.H. wrote the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data associated with this study are present in the paper or the Supplementary Materials. Data from downstream analyses are available in data files S1 to S6.

Submitted 25 May 2019
Resubmitted 04 November 2019
Accepted 16 July 2020
Published 5 August 2020
10.1126/scitranslmed.aax8096

Citation: Z. Zhou, T. M. Moore, B. G. Drew, V. Ribas, J. Wanagat, M. Civelek, M. Segawa, D. M. Wolf, F. Norheim, M. M. Seldin, A. R. Strumwasser, K. A. Whitney, E. Lester, B. R. Reddish, L. Vergnes, K. Reue, P. Rajbhandari, P. Tontonoz, J. Lee, S. K. Mahata, S. C. Hewitt, O. Shirihai, C. Gastonbury, K. S. Small, M. Laakso, J. Jensen, S. Lee, C. A. Drevon, K. S. Korach, A. J. Lusis, A. L. Hevener, Estrogen receptor α controls metabolism in white and brown adipocytes by regulating *Polg1* and mitochondrial remodeling. *Sci. Transl. Med.* **12**, eaax8096 (2020).

Estrogen receptor α controls metabolism in white and brown adipocytes by regulating *Polg1* and mitochondrial remodeling

Zhenqi Zhou, Timothy M. Moore, Brian G. Drew, Vicent Ribas, Jonathan Wanagat, Mete Civelek, Mayuko Segawa, Dane M. Wolf, Frode Norheim, Marcus M. Seldin, Alexander R. Strumwasser, Kate A. Whitney, Ellen Lester, Britany R. Reddish, Laurent Vergnes, Karen Reue, Prashant Rajbhandari, Peter Tontonoz, Jason Lee, Sushil K. Mahata, Sylvia C. Hewitt, Orian Shirihai, Craig Gastonbury, Kerrin S. Small, Markku Laakso, Jorgen Jensen, Sindre Lee, Christian A. Devon, Kenneth S. Korach, Aldons J. Lusis and Andrea L. Hevener

Sci Transl Med **12**, eaax8096.
DOI: 10.1126/scitranslmed.aax8096

Estrogen receptor energetics

The estrogen receptor α (ER α ; encoded by *ESR1*) is implicated in aging-related obesity. Zhou *et al.* now provide evidence that ER α affects metabolism by controlling mitochondrial dynamics and function in both white and brown adipose tissue. Expression of *ESR1* in adipose tissue associated with reduced visceral adiposity and increased insulin sensitivity in two independent human cohorts and a panel of mice. Follow-up experiments in mice indicated that *Esr1* deletion in white adipose tissue promoted parkin-driven mitophagy, whereas *Esr1* deletion in brown adipose tissue reduced thermogenesis. Mechanistically, the authors tied these metabolic responses to direct ER α -driven control of a mitochondrial DNA polymerase subunit in both types of fat.

ARTICLE TOOLS	http://stm.sciencemag.org/content/12/555/eaax8096
SUPPLEMENTARY MATERIALS	http://stm.sciencemag.org/content/suppl/2020/08/03/12.555.eaax8096.DC1
RELATED CONTENT	http://stm.sciencemag.org/content/scitransmed/12/528/eaau5956.full http://stm.sciencemag.org/content/scitransmed/11/496/eaav1892.full http://stm.sciencemag.org/content/scitransmed/11/510/eaav5055.full
REFERENCES	This article cites 72 articles, 15 of which you can access for free http://stm.sciencemag.org/content/12/555/eaax8096#BIBL
PERMISSIONS	http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the [Terms of Service](#)

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works